|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 1634 I Street, NW |
Address2 | Suite 1200 |
City | Washington |
State | DC |
Zip Code | 20006 |
Country | USA |
3. Principal place of business (if different than line 2)
City | |
State | |
Zip Code | |
Country | |
|
5. Senate ID# 30187-1004416
|
||||||||
|
6. House ID# 306800147
|
TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Mr. Thomas M. Ryan, Managing Partner |
Date | 04/16/2012 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
P.L. 111-148- Patient Protection and Affordable Care Act of 2009 (ACA); P.L. 111-152- The Health Care & Education Affordability Reconciliation Act of 2010: Issues regarding comparative effectiveness, Prescription Drug User Fee Act reauthorization, prescription drug reimportation generally, implementation of Physician Payment Sunshine provisions and Prescription Drug Sample transparency reporting provisions.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thomas |
Ryan |
|
|
|
Jeff |
MacKinnon |
|
|
|
Joe |
Vasapoli |
|
|
|
Matthew |
Berzok |
|
|
|
Nick |
Kolovos |
|
|
|
Jeff |
Mortier |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H. R. 1249 and S. 23- America Invents Act
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thomas |
Ryan |
|
|
|
Jeff |
MacKinnon |
|
|
|
Joe |
Vasapoli |
|
|
|
Matthew |
Berzok |
|
|
|
Nick |
Kolovos |
|
|
|
Jeff |
Mortier |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
Supporting Increasing funding opportunities for better care and treatment of people with diabetes in P.L. 111-148, Patient Protection
and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010:
Issues related to diabetes generally, and specifically minority health, diabetes screening, National Diabetes Prevention Program,
National Prevention Strategy, Medicaid Quality Measures, Medicare Annual Wellness Visit, ACOs - related to Medicare Share
Savings Program, Coverage of Preventive Services under ACA, HHS Strategic Plan, HHS Multiple Chronic Conditions
Framework, National Quality Strategy, Prevention and Public Health Fund, Diabetes Prevention Issues in a Survey of Primary
Care Physicians, Adequate Inclusion of Diabetes Care in the Essential Health Benefits Package, IOM Committee on Valuing
Community-based Non-Clinical Prevention Policies and Wellness Strategies, DOL Survey of Employer-Sponsored Health
Insurance Coverage, CDC National Survey of Primary Care Policies for Managing Patients with Higher Blood Pressure, High
Cholesterol, or Diabetes (NSPCP); H.R. 2954, the Health Equity and Accountability Act of 2011; H.R. 2960 National Diabetes
Clinical Care Commission Act; S. 1559 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act FY2012.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Natl Institutes of Health (NIH), Health & Human Services - Dept of (HHS), Labor - Dept of (DOL)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thomas |
Ryan |
|
|
|
Jeff |
MacKinnon |
|
|
|
Joe |
Vasapoli |
|
|
|
Matthew |
Berzok |
|
|
|
Nick |
Kolovos |
|
|
|
Jeff |
Mortier |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA); P.L. 111-152, The Health Care & Education Affordability
Reconciliation Act of 2010: biosimilar provisions
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thomas |
Ryan |
|
|
|
Jeff |
MacKinnon |
|
|
|
Joe |
Vasapoli |
|
|
|
Matthew |
Berzok |
|
|
|
Nick |
Kolovos |
|
|
|
Jeff |
Mortier |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
FY12 Budget Resolution: diabetes-related issues and issues relating to modernizing cost estimates with respect to preventive health
legislation. H.R. 3675 Temporary Pay Reduction Act of 2011 provisions.
Debt reduction proposals to extend Medicaid rebate to Part D.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thomas |
Ryan |
|
|
|
Jeff |
MacKinnon |
|
|
|
Joe |
Vasapoli |
|
|
|
Matthew |
Berzok |
|
|
|
Nick |
Kolovos |
|
|
|
Jeff |
Mortier |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare Diabetes Screening; H.R. 2741, Preventing Diabetes in Medicare Act of 2011 and Prediabetes generally; Issues related to
Medicaid rebates and similar revenue provisions as contained in P.L. 112-25, Budget Control Act of 2011, P.L. 111-148, Patient
Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152,
The Health Care & Education Affordability Reconciliation Act of 2010: issues related to the 340B program, CMS Proposed
Coverage Decision Memorandum for Intensive Behavioral Therapy for Obesity.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thomas |
Ryan |
|
|
|
Jeff |
MacKinnon |
|
|
|
Joe |
Vasapoli |
|
|
|
Matthew |
Berzok |
|
|
|
Nick |
Kolovos |
|
|
|
Jeff |
Mortier |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code LAW
16. Specific lobbying issues
S. 1002 SAFE DOSES Act (Modernizing criminal laws concerning theft of medical products)
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thomas |
Ryan |
|
|
|
Jeff |
MacKinnon |
|
|
|
Joe |
Vasapoli |
|
|
|
Matthew |
Berzok |
|
|
|
Nick |
Kolovos |
|
|
|
Jeff |
Mortier |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 436- Protect Medical Innovation Act of 2011
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES,
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Thomas |
Ryan |
|
|
|
Jeff |
MacKinnon |
|
|
|
Joe |
Vasapoli |
|
|
|
Matthew |
Berzok |
|
|
|
Nick |
Kolovos |
|
|
|
Jeff |
Mortier |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address | |
||||||
City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |